• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

166.43 -0.10 (-0.06%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,588,918
Open 168.28
Bid (Size) 166.43 (100)
Ask (Size) 170.90 (100)
Prev. Close 166.53
Today's Range 165.80 - 170.24
52wk Range 116.94 - 176.58
Shares Outstanding 1,253,809,440
Dividend Yield 1.97%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lakefront Biotherapeutics Eyes 2027 Trials for Autoimmune Drug, Backed by €2.2 Billion in Cash ↗
Today 22:12 EST
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) is preparing to expand testing of its autoimmune drug candidate gamgertamig, with executives pointing to clinical data, potential... 
Via MarketBeat
News headline image
Gilead Sciences Maps Growth Beyond BIKTARVY With HIV, Cancer and Inflammation Drugs ↗
November 17, 2026
Gilead Sciences (NASDAQ:GILD) expects HIV and oncology to drive growth through the rest of the decade while it builds an inflammation business for the 2030s, executives said at a London healthcare... 
Via MarketBeat
Topics Intellectual Property

Performance

52-Week Range 5.7% below 52-week high
166.43
116.9452W Low 176.5852W High
1 Week 3.1% below 1-week high
164.801W Low 171.801W High

Gilead Sciences (GILD) traded between $116.94 and $176.58 over the past 52 weeks and last traded at $166.43, 5.7% below its 52-week high. Over the past week it ranged between $164.80 and $171.80.

Past 12 Months
-0.7%
+5.9%
+13.4%
+24.5%
+36.9%
+31.4%
1W -$1.15
1M +$9.24
3M +$19.69
6M +$32.70
YTD +$44.83
1Y +$39.79

GILD was +31.4% over the past year, +24.5% over six months, +36.9% year to date, -0.7% in the last week.

12 Months vs Market
GILD
+31.4%
DIA
+4.0%
SPY
+4.7%
QQQ
+3.1%
IWM
+8.9%

Over the past 12 months GILD returned +31.4% versus DIA (Dow) +4.0%, SPY (S&P 500) +4.7%, QQQ (Nasdaq 100) +3.1% and IWM (Russell 2000) +8.9%.

Volume & Liquidity 1.26× 3-mo avg
Today 7,588,918 3-mo avg 6.0M
1W
5.7M
1M
6.4M
3M
6.0M
6M
6.8M
YTD
6.8M
1Y
6.8M

GILD most recently traded 7,588,918 shares against a 3-month average daily volume of 6.0M.

More News

Read More
News headline image
Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwind ↗
November 17, 2026
Via MarketBeat
News headline image
These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys ↗
November 16, 2026
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing
November 16, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
3 Pharmaceutical Stocks That Offer Safety and Growth ↗
November 12, 2026
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Gilead Brings HIV Prevention to the 27th Annual Latin GRAMMY Awards®
November 12, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom ↗
November 11, 2026
Via MarketBeat
Topics Artificial Intelligence Bankruptcy
News headline image
Gilead Sciences Targets 200 Treatment Centers for Potential Anito-Cel Launch ↗
November 10, 2026
Via MarketBeat
News headline image
Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy? ↗
November 10, 2026
Via The Motley Fool
Topics Stocks
News headline image
Vir, A Gilead Rival, Shoots To Two-Year High On Its 'Clean Win' In Hepatitis D Treatment ↗
November 09, 2026
Via Investor's Business Daily
News headline image
Compugen (CGEN) Q3 2026 Earnings Call Transcript ↗
November 09, 2026
Via The Motley Fool
Topics Earnings
News headline image
Gabelli Releases Agenda for 8th Annual Healthcare Symposium
November 09, 2026
From Gabelli Funds
Via GlobeNewswire
News headline image
The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation ↗
November 08, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
November 06, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Vir Bio (VIR) Q3 2026 Earnings Call Transcript ↗
November 05, 2026
Via The Motley Fool
Topics Earnings
News headline image
Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)
November 05, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe. ↗
November 05, 2026
Via The Motley Fool
News headline image
What Vir Biotechnology (VIR) Said on Its Q3 Earnings Call ↗
November 05, 2026
Via MarketBeat
Topics Earnings
News headline image
3 S&P 500 stocks we think twice about
November 04, 2026
Via StockStory
Topics Stocks
News headline image
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
November 04, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
2 Nasdaq 100 stocks to own for decades and 1 we brush off
November 02, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
United Therapeutics (UTHR) to report earnings tomorrow: here is what to expect
November 02, 2026
Via StockStory
News headline image
Earnings to watch: Myriad Genetics (MYGN) reports Q3 results tomorrow
November 02, 2026
Via StockStory
News headline image
Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
November 02, 2026
From Gilead Sciences, Inc.
Via Business Wire

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 166.43
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 11/20/26 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 208.67B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 209B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap